|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1991-10-24
|
|
pubmed:abstractText |
The GABAergic drug baclofen and the cholinergic drug physostigmine were administered to patients with upbeat and downbeat nystagmus. Baclofen (orally, 5 mg three times daily) reduced nystagmus slow phase velocity and distressing oscillopsia by 25-75% in four out of five patients (two upbeat nystagmus; two downbeat nystagmus). Physostigmine (1 mg single intravenous injection) increased nystagmus in five additional patients with downbeat (1) or positional downbeat nystagmus (4) for a duration of 15-20 minutes. The different interactions of baclofen and physostigmine on neurotransmission subserving vertical vestibulo-ocular reflex could account for these effects. The response to baclofen appears to be a GABA-B-ergic effect with augmentation of the physiological inhibitory influence of the vestibulo-cerebellum on the vestibular nuclei. Similarly baclofen has an inhibitory effect on the velocity storage mechanism. Cholinergic action may cause the increment of nystagmus by physostigmine.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-108122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-12325208,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-1694327,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3377447,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3399085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3446808,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-348269,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3484626,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3488729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3492476,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3504267,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3759419,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3822146,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3827215,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3871968,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-3877148,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-404173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-415281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-4360381,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-4591431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-519514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-519515,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-556821,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-6103949,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-6213659,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-6283039,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-6626994,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-6626995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-6769690,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-6970904,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-6978641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-7064710,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-7212648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-7224968,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-7288469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1654396-864038
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0022-3050
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
627-32
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1654396-Adult,
pubmed-meshheading:1654396-Aged,
pubmed-meshheading:1654396-Baclofen,
pubmed-meshheading:1654396-Biperiden,
pubmed-meshheading:1654396-Cerebellum,
pubmed-meshheading:1654396-Electrooculography,
pubmed-meshheading:1654396-Female,
pubmed-meshheading:1654396-Humans,
pubmed-meshheading:1654396-Male,
pubmed-meshheading:1654396-Middle Aged,
pubmed-meshheading:1654396-Neural Pathways,
pubmed-meshheading:1654396-Nystagmus, Pathologic,
pubmed-meshheading:1654396-Physostigmine,
pubmed-meshheading:1654396-Receptors, Cholinergic,
pubmed-meshheading:1654396-Receptors, GABA-A,
pubmed-meshheading:1654396-Reflex, Vestibulo-Ocular,
pubmed-meshheading:1654396-Vestibular Nuclei
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus.
|
|
pubmed:affiliation |
Department of Neurology, Klinikum Grosshadern, University of Munich, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
